<DOC>
	<DOCNO>NCT02623647</DOCNO>
	<brief_summary>The present phase I-II study test safety efficacy extremely hypofractionated radiotherapy early stage prostate cancer . The study design assess GU toxicity control tumor control , term survival free biochemical failure . 40 Gy fxs deliver patient low favourable intermediate risk prostate tumor .</brief_summary>
	<brief_title>A Phase I-II Study Stereotactic Body Radiotherapy 3 Fractions Low/Int Risk Prostate Cancer</brief_title>
	<detailed_description>In last two decade several study show exclusive sensitivity prostate cancer cell low dos per fraction . It postulate effect fractionation protective tumor cell rather acute late responding normal tissue , turn tend decrease therapeutic index . The schedule test consider biologically equivalent deliver tumor , 2 Gy per fraction , total dose approximately 170 Gy twice reference schedule ( 76-80 Gy ) . On contrary , schedule consider deliver dose 78 Gy 130 Gy acute ( i.e mucosa ) ( a/b =10 Gy ) late ( a/b =3 Gy ) ( i.e . rectum , bladder ) respond tissue . Main selection criterion : Patients ( &gt; 18 yrs/old ) low risk ( primary tumor stage accord AJCC 2010 : T1-2a Gleason Score-GLS : 3+3 serum Prostate Specific Antigen-PSA : PSA &lt; 10 ng/ml ) among intermediate risk feature ( clinical stage T2b-c GLS 7 PSA 10-20 ng/ml ) favorable one ( single factor intermediate risk GLS 3 + 4 &lt; 50 % biopsy core contain cancer ) select . Work &amp; pretreatment procedure : A diagnostic biopsy least 10 core need . Patients undergo local anesthesia placement 4 fiducials ( 'gold seed ' ) gel spacer prostate rectum least one week simulation . Both seek gel spacer implant throughout perineum . The gel insert posterior aspect prostate anterior rectal wall obtain space least 5 mm thickness two structure . Treatment outline : Patients treat EBRT , Volumetric Arc Radiotherapy prostate total dose 40 Gy 3 fraction , every day ( dose per fraction=13.3 Gy ) . While neoadjuvant androgen deprivation allow 3 month , concomitant/adjuvant ( eHYPO ) androgen deprivation allow . Simulation &amp; Planning : Patients undergo CT MR pelvis planning purpose , supine position . The clinical target volume ( CTV ) represent prostate identify MR image ( coregistered CT ) . During CT MR scan patient catheterize ( identify urethra ) bladder fill saline , 250 cc . The prostate ( target ) contour MR expand 4 mm isotropically plan purpose obtain Planning Target Volume ( PTV ) . The rectal wall , bladder wall , bladder trigone , prostate urethra , intestinal cavity , rectal spacer , penile bulb , femoral head contour well . The treatment plan Volumetric Arc Modulated Therapy . Before treatment fraction , correct set prostate do compare spatial position 4 fiducials plan CT CBCT . Patients see treatment , one month treatment completion every three month afterwards 2 yr . Serum PSA obtain follow treatment . Regarding disease control , outcome compute term biochemical control free survival , survival biochemical control . This define accord 'Phoenix ' definition 'nadir plus 2 ng/ml ' . Toxicity record CTCAE v4.0 examination . Before treatment 12 24 month follow ups patient report QoL ( EORTC FACT-P ) , IPSS , urinary continence ( ICIQ-SF ) sexual activity ( IIEFS ) . At 12 24 month ask report satisfaction treatment ( FACIT-I ) .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>age ( &gt; 18 yrs/old ) low risk prostate cancer define primary tumor stage accord AJCC 2010 : T12a Gleason ScoreGLS : 3+3 serum Prostate Specific AntigenPSA : PSA &lt; 10 ng/ml ) ; among intermediate risk prostate cancer define clinical stage T2bc GLS 7 PSA 1020 ng/ml , patient favourable characteristic : single factor intermediate risk AND GLS 3 + 4 AND &lt; 50 % biopsy core contain cancer ( 12 core minimum ) . prior radiotherapy concomitant androgen deprivation pt failure consent</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>